Phase 1 clinical study of GS-1614 in healthy volunteers determining optimal dose, safety profile and frequency of administration.
Latest Information Update: 17 Jun 2024
At a glance
- Drugs GS 1614 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 17 Jun 2024 New trial record